Abstract
Although renal Fanconi syndrome resulting from valproate (VPA) has occasionally been reported, the detailed clinical characteristics of this disease remain unclear. To clarify the clinical features of patients with VPA-induced Fanconi syndrome, we analyzed the clinical and laboratory data of seven affected patients. All patients were children, were severely disabled and required tube feeding. Five patients required treatment with multiple anticonvulsant agents. Hypophosphatemia and hypouricemia were found in all patients. Mild proteinuria, increased excretion of urinary β2-microglobulin (β2MG) and generalized hyperaminoaciduria were present in all patients. The renal biopsy of one patient exhibited tubulointerstitial nephritis without any structural abnormalities of the mitochondria in proximal renal tubular cells. All patients recovered from the Fanconi syndrome after the cessation of VPA therapy without any long-term renal sequellae. These results indicate that young age and being severely disabled with tube feeding and anticonvulsant polytherapy are contributory factors to the development of VPA-induced Fanconi syndrome. Serum phosphate and uric acid concentrations and urinary β2MG levels in addition to serum electrolytes and urinalysis should be examined regularly in patients receiving VPA therapy, especially in those with the contributory factors outlined above. Patients with Fanconi syndrome caused by VPA have a favorable renal outcome.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dreifuss FE, Langer DH (1988) Side effects of valproate. Am J Med 84 [Suppl 1A]:34–41
Lenoir GR, Pèrignon JL, Gubler MC, Broyer M (1981) Valproic acid: a possible cause of proximal tubular renal syndrome. J Pediatr 98:503–504
Lande MB, Kim MS, Bartlett C, Guay-Woodford LM (1993) Reversible Fanconi syndrome associated with valproate therapy. J Pediatr 123:320–322
Arita K, Kita T, Maeyama M, Adachi K (1996) Fanconi syndrome during valproate therapy (in Japanese). Shonika Rinsho 49:120–124
Yoshikawa H, Watanabe T, Abe T (2002) Fanconi syndrome caused by sodium valproate: report of three severely disabled children. Eur J Paediatr Neurol 6:165–167
Zaki EL, Springate JE (2002) Renal injury from valploic acid: case report and literature review. Pediatr Neurol 27:318–319
Smith GC, Balfe JW, Kooh SW (1995) Anticonvulsants as a cause of Fanconi syndrome. Nephrol Dial Transplant 10:543–545
Lin CY, Chiang H (1988) Sodium-valproate-induced interstitial nephritis. Nephron 48:43–46
Yoshiya K, Nakazawa S, Yoshioka M, Yoshikawa N (1994) Tobulo-interstitial nephritis caused by sodium valproate (in Japanese). Shonika Shinryo 57:285–288
Hawkins E, Brewer E (1993) Renal toxicity induced by valproic acid (Depakene). Pediatr Pathol 13:863–868
Fukuda Y, Watanabe H, Ohtomo Y, Yabuta K (1996) Immunologically mediated chronic tubulo-interstitial nephritis caused by valproate therapy. Nephron 72:328–329
Yoshikawa H, Watanabe T, Abe T (2002) Tubulo-interstitial nephritis caused by sodium valproate. Brain Dev 24:102–105
Foreman JW (2004) Cystinosis and Fanconi syndrome. In: Avner ED, Harmon WE, Niaudet P (eds) Pediatric nephrology, 5th edn. Lippincott Williams and Wilkins, Philadelphia, pp 789–806
Brodehl J (1992) The Fanconi syndrome. In: Edelmann CM Jr (eds) Pediatric kidney disease. Little Brown, Boston, pp 1841–1869
Novo MLP, Izumi T, Yokota K, Fukuyama Y (1993) Urinary excretion of N-acetyl-β-glucosaminidase and β-galactosidase by patients with epilepsy. Brain Dev 15:157–160
Korinthenberg R, Wehrle L, Zimmerhackl LB (1994) Renal tubular dysfunction following treatment with anti-epileptic drugs. Eur J Pediatr 153:855–858
Altunbaşak Ş, Yıldızdaş D, Anarat A, Burgut HR (2001) Renal tubular dysfunction in epileptic children on valproic acid therapy. Pediatr Nephrol 16:256–259
Niaudet P, Rötig A (1997) The kidney in mitochondrial cytopaties. Kidney Int 51:1000–1007
Anderson GD (2002) Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia 43 [Suppl 3]:53–59
Igarashi N, Sato T, Kyouya S (1990) Secondary carnitine deficiency in handicapped patients receiving valproic acid and/or elemental diet. Acta Paediatr Jpn 32:139–145
Feller AG, Rudman D, Erve PR, Johnson RC, Boswell J, Jackson DL, Mattson DE (1987) Subnormal concentrations of serum selenium and plasma carnitine in chronically tube-fed patients. Am J Clin Nutr 45:476–483
Tanaka S, Miki T, Hsieh ST, Kim JI, Yasumoto T, Taniguchi T, Ishikawa Y, Yokoyama M (2003) A case of severe hyperlipidemia caused by long-term tube feedings. J Atheroscler Thromb 10:321–324
Ohtani Y, Endo F, Matsuda I (1982) Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J Pediatr 101:782–785
Matsuda I, Ohtani Y, Ninomiya N (1986) Renal handling of carnitine in children with carnitine deficiency and hyperammonemia associated with valproate therapy. J Pediatr 109:131–134
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Watanabe, T., Yoshikawa, H., Yamazaki, S. et al. Secondary renal Fanconi syndrome caused by valproate therapy. Pediatr Nephrol 20, 814–817 (2005). https://doi.org/10.1007/s00467-005-1827-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-005-1827-7